

Outlook Therapeutics, Inc. Logo

Oncobiologics to Present at the World Biosimilar Congress 2017

May 9, 2017

CRANBURY, N.J., May 09, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, today announced that Pankaj Mohan, Ph.D., Chairman and Chief Executive Officer of Oncobiologics, will participate and present at the World Biosimilar Congress 2017 taking place May 23 – 24, 2017.

Event: The World Biosimilar Congress 2017

Presentation Date: May 23-24, 2017

Location: Hilton San Diego Resort and Spa, San Diego, CA

Dr. Mohan will present on "Production efficiency: Streamlining both the development and manufacturing process," on May 23rd at 3:20 p.m. On the same day, Dr. Mohan will also participate in a panel discussion on Intellectual Property at 5:00 p.m. On May 24th at noon, he will moderate a roundtable discussion of industry executives on "Achieving required data for regulatory and commercial approvals."

World Biosimilar Congress 2017

To learn more about the World Biosimilar Congress and to register for the conference please visit <http://www.terrapinn.com/conference/biosimilar-congress-usa/index.stm>

About Oncobiologics, Inc. and its BioSymphony™ Platform

Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Its current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. Oncobiologics is advancing its pipeline of eight biosimilar products, two of which are currently in clinical development. Led by a team of biopharmaceutical experts, Oncobiologics operates from an in-house state-of-the-art fully integrated research and development, and manufacturing facility in Cranbury, New Jersey. Oncobiologics employs its BioSymphony™ Platform to address the challenges of biosimilar development and commercialization by developing high quality mAb biosimilars in an efficient and cost-effective manner on an accelerated timeline. For more information, please visit www.oncobiologics.com

CONTACTS:

Oncobiologics:

Lawrence A. Kenyon

Chief Financial Officer

LawrenceKenyon@oncobiologics.com

Media & Investors:

Alex Fudukidis

Russo Partners, LLC

alex.fudukidis@russopartnersllc.com



Oncobiologics, Inc.